<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297502</url>
  </required_header>
  <id_info>
    <org_study_id>SYM 2016-01</org_study_id>
    <nct_id>NCT03297502</nct_id>
  </id_info>
  <brief_title>Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis</brief_title>
  <official_title>Multicenter Study of the Safety and Bioequivalence of Par's Pimecrolimus Cream, 1% and RLD Elidel® (Pimecrolimus Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in Treatment of Mild to Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3, double-blind, randomized, parallel-group, placebo-controlled, multicenter study to
      evaluate the safety and bioequivalence of Par Pharmaceutical Inc.'s Pimecrolimus Cream, 1%
      and Reference Listed Elidel® (Pimecrolimus Cream, 1%). The study compares both active
      treatments to a placebo control in the treatment of mild to moderate atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with treatment success in each treatment group</measure>
    <time_frame>Day 15</time_frame>
    <description>Treatment success is defined as an Investigator's Global Assessment (IGA) Rating of &quot;clear&quot; or &quot;almost clear&quot; ( i.e., a score of 0 or 1 on a scale of 0 [clear] through 4. IGA Scale: 0 = Clear (minor discoloration, no erythema, induration, population, oozing/crusting. 1= Almost Clear (trace, faint erythema, almost no induration/population, no oozing/crusting. 2 = Mild (faint erythema, mild induration/population, no oozing/crusting. 3 = Moderate (Pink-red erythema, moderate induration/population, some oozing/crusting. 4 = Severe (Deep/bright erythema, severe induration/population, with oozing/crusting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in severity (erythema)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Change from baseline in severity in clinical signs and symptoms of erythema is assessed.
0 = None: No erythema present
= Mild: Slight erythema, very light-pink
= Moderate: Dull red, clearly distinguishable
= Severe: Deep/dark red</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in severity (induration/population)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Change from baseline in severity in clinical signs and symptoms of induration/papulation is assessed.
0 = None: No elevation
= Mild: Slightly perceptible elevation
= Moderate: Clearly perceptible elevation
= Severe: Marked and extensive elevation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in severity (lichenification)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Change from baseline in severity in clinical signs and symptoms of lichenification is assessed.
0 = None: No lichenification
= Mild: Slight thickening of the skin discernible only by touch and with skin markings minimally exaggerated
= Moderate: Definite thickening of the skin with skin markings exaggerated so that they form a visible criss-cross pattern
= Severe: Thickened indurated skin with skin markings visibly portraying an exaggerated criss-cross pattern</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in severity (pruritis)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Change from baseline in severity in clinical signs and symptoms of puritus is assessed.
0 = None: No itching
= Mild: Occasional, slight itching/scratching
= Moderate: Constant or intermittent itching/scratching/discomfort that is not disturbing sleep
= Severe: Bothersome itching/scratching/discomfort that is disturbing sleep</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">582</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Pimecrolimus cream, 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Elidel (pimecrolimus) cream 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pimecrolimus cream 1%</intervention_name>
    <arm_group_label>Pimecrolimus cream, 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elidel (pimecrolimus) cream 1%</intervention_name>
    <arm_group_label>Elidel (pimecrolimus) cream 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to provide written informed consent/assent for the study.

          2. Non-immunocompromised male or female aged 12 years or older.

          3. A clinical diagnosis of mild to moderate atopic dermatitis that has failed to respond
             adequately to other topical prescription treatments for atopic dermatitis, or subjects
             for whom the use of those other treatments is deemed inadvisable.

          4. A diagnosis of atopic dermatitis for at least 3 months.

          5. A baseline Investigator's Global Assessment (IGA) of disease severity of mild or
             moderate (score of 2 or 3). (See Section 9.6.10 for the scale.)

          6. An affected area of atopic dermatitis involvement of at least 5% of the body surface
             area (BSA) at Visit 2/Day 1 (Baseline), as defined by the criteria of Hanifin and
             Rajka (1980).

          7. Treatment with a bland emollient for at least 7 days prior to Visit 2/Day 1
             (Baseline).

          8. Agree to adhere to protocol-specified requirements and concomitant therapy
             restrictions.

          9. Willing to avoid constant sun exposure and the use of tanning booths or other UV light
             sources during participation in the study.

         10. In general good health, non-immunocompromised, and free from any clinically
             significant disease, other than atopic dermatitis, that might interfere with the study
             evaluations.

         11. Willing and able to understand and comply with the requirements of the study, apply
             the study medication as instructed, return for the required study visits, comply with
             therapy prohibitions, and complete the study.

         12. Female subjects of childbearing potential (excluding women who are surgically
             sterilized [hysterectomy, bilateral tubal ligation, or bilateral ovariectomy] or have
             been postmenopausal for at least 1 year) must have a negative urine pregnancy test and
             must be willing to use a medically accepted method of contraception during the study.
             The following are considered acceptable methods of birth control for the purpose of
             this study: oral contraceptives, contraceptive patches, contraceptive implant, vaginal
             contraceptive, double barrier methods (e.g., condom and spermicide), contraceptive
             injection (Depo-Provera®), intrauterine device (IUD), hormonal IUD (Mirena®), Essure®
             permanent birth control, and abstinence with a documented second acceptable method of
             birth control if the subject becomes sexually active.

        Exclusion Criteria:

          1. Females who are pregnant, breastfeeding, intending to become pregnant during the
             study, or who do not agree to use an acceptable form of birth control during the
             study.

          2. Active cutaneous bacterial or viral infection in any proposed treatment area at Visit
             2/Baseline (e.g., clinically infected atopic dermatitis).

          3. Sunburn, extensive scarring, or pigmented lesion(s) in any treatment area at Visit
             2/Baseline that would interfere with the study evaluations.

          4. History of confounding skin conditions, e.g., psoriasis, rosacea, erythroderma, or
             ichthyosis.

          5. History or presence of Netherton's Syndrome, immunological deficiencies or diseases,
             HIV, diabetes, malignancy, serious active or recurrent infection, clinically
             significant severe renal insufficiency, or severe hepatic disorders.

          6. Use of any treatment listed in Table 9.1 more recently than the indicated washout
             period prior to Visit 2/Baseline.

          7. Need or intent to continue to use any treatment listed in Table 9.1 during the current
             study.

             Table 9.1 Medications, Supplements, and Other Substances Prohibited for Study Entry
             Prohibited Medications, Supplements, and Other Substances Washout Period Prior to
             Randomization Visit 2/Baseline

               -  Systemic corticosteroids (oral and injectable [intravenous and intramuscular])
                  (Intranasal and Inhalational steroids are allowed if use is kept constant during
                  the study)

               -  UVA/UVB therapy

               -  PUVA (psoralen plus ultraviolet A) therapy

               -  Tanning booths

               -  Nonprescription UV light sources

               -  Immunomodulators or immunosuppressive therapies

               -  Interferon

               -  Cytotoxic drugs (e.g., methotrexate, cyclophosphamide, azathioprine)

               -  Oral retinoids

               -  Systemic anti-fungals

               -  Tacrolimus

               -  Pimecrolimus 30 days (1 month)

               -  Systemic antibiotics

               -  Topical calcipotriene or other topical vitamin D preparations

               -  Topical retinoids 14 days (2 weeks)

               -  Topical and oral antihistamines

               -  Topical antibiotics

               -  Topical corticosteroids

               -  Topical antifungals

               -  Other topical drug products 7 days (1 week)

               -  Any topical product (e.g., sunscreens, lotions, creams) in areas to be treated
                  except for bland emollient (moisturizer)

               -  Grapefruit or grapefruit juice which is considered a CYP3A inhibitor 24 hours

          8. Current use of calcium channel blockers (e.g, amlodipine, nifedipine, verapamil,
             diltiazem, felodipine, isradipine, nisoldipine, etc) and/or cimetidine (e.g., Tagamet)
             which are CPY3A inhibitors.

          9. Known allergy or hypersensitivity to pimecrolimus or any other component of the Test
             or Reference product.

         10. Unwilling to minimize or avoid natural and artificial sunlight exposure during
             treatment.

         11. Consumption of excessive alcohol, abuse of drugs, or a condition that could compromise
             the subject's ability to comply with study requirements.

         12. Any clinically significant condition or situation other than the condition being
             studied that, in the opinion of the investigator, would interfere with the study
             evaluations or optimal participation in the study.

         13. Use of any investigational drug or investigational device within 30 days prior to
             Visit 2/Baseline.

         14. Previous participation in this study.

         15. Employees of the research center or investigator.

         16. Family members of employees of the research center or investigator.

         17. Family members living in the same household participating at the same time.

        Table 9.2 Medications (Prescription and Over-the-Counter), Supplements, and Other
        Substances Prohibited During the Study Prohibited Medications, Supplements, and Other
        Substances Treatment for atopic dermatitis other than assigned study medication or bland
        emollient.

        Topical or systemic (oral and injectable) corticosteroid (Intranasal and inhalational
        steroids are allowed if kept constant during the study) Topical or systemic antibiotic
        Topical or systemic antifungal Topical or oral antihistamine (e.g., diphenhydramine,
        hydroxyzine) Immunosuppressive drugs Immunomodulator (e.g., tacrolimus) Calcipotriene or
        other topical vitamin D preparations Topical or oral retinoids Interferon Cyclosporine
        Methotrexate Azathioprine CPY3A inhibitor (e.g., erythromycin, itraconazole, ketoconazole,
        fluconazole, calcium channel blockers, cimetidine, grapefruit or grapefruit juice) Topical
        product other than assigned study medication or bland emollient (e.g., sunscreen, new brand
        of cosmetic or cleanser, cream, lotion, ointment, or powder) applied on or near the
        treatment area(s) Phototherapy (e.g., PUVA, UVA or UVB therapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Davis, MD, RPh</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

